|
KMID : 1146320150030020099
|
|
Journal of Health Technology Assessment
2015 Volume.3 No. 2 p.99 ~ p.106
|
|
|
Methicillin-Resistant Staphylococcus Aureus 감염으로 인한 병원 내 감염 폐렴 치료제로서 Linezolid와 Vancomycin의 비용-효과 분석
|
|
Park Ji-Hyun
Jeong Jae-Hong
Hwang Sung-Hye
|
|
|
Abstract
|
|
|
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) is considered to be the primary cause of hospital acquired pneumonia (HAP) and MRSA-associated HAP occur a significant impact on healthcare resource use and associated economic costs. The objective of this study was to investigate the economic impact of linezolid compared with that of vancomycin in the treatment of hospitalized patients with MRSA-confirmed HAP in the Korea.
Methods: A 30-days decision tree model incorporated published data on clinical parameters, resource use, and costs were constructed. The base case first-line treatment duration for patients with hospital-acquired pneumonia was 10 days. Treatment success, discontinuation due to adverse events, discontinuation due to lack of efficacy, and mortality were possible outcomes that could impact costs.
Results: The model calculated that linezolid was associated with an 1.8% higher cure rate compared with vancomycin (62.5% vs. 60.7%, respectively). Average total costs per episode for linezolid-and vancomycin-treated patients were KRW 3420971 and 3459977 respectively. The incremental cost-effectiveness ratio favored linezolid (versus vancomycin), with marginally lower costs (by KRW 39006) and greater efficacy (+1.8% absolute difference in the proportion of patients successfully treated for MRSA HAP).
Conclusion: The study shows that linezolid is a cost-effective alternative to vancomycin for HAP.
|
|
|
KEYWORD
|
|
|
Cost-effective analysis, Hospital-acquired pneumonia, Nosocomial pneumonia, Linezolid, Vancomycin
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|